

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer

Campbell S.D. Roxburgh^{a,*}, Jonathan M. Salmond^b, Paul G. Horgan^a, Karin A. Oien^b, Donald C. McMillan^a

^aUniversity Department of Surgery, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, United Kingdom

^bUniversity Department of Pathology, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom

ARTICLE INFO

Article history:

Received 11 February 2009

Received in revised form 1 April 2009

Accepted 2 April 2009

Available online 4 May 2009

Keywords:

Colorectal cancer

Survival

Prognosis

Inflammation

Pathology

ABSTRACT

Background: A pronounced tumour inflammatory infiltrate is known to confer a good outcome in colorectal cancer. Klintrup and colleagues reported a structured assessment of the inflammatory reaction at the invasive margin scoring low grade or high grade. The aim of the present study was to examine the prognostic value of tumour inflammatory infiltrate in node-negative colorectal cancer.

Methods: Two hundred patients had undergone surgery for node-negative colorectal cancer between 1997 and 2004. Specimens were scored with Jass' and Klintrup's criteria for peritumoural infiltrate. Pathological data were taken from the reports at that time.

Results: Low-grade inflammatory infiltrate assessed using Klintrup's criteria was an independent prognostic factor in node-negative disease. In patients with a low-risk Petersen Index ($n = 179$), low-grade infiltrate carried a threefold increased risk of cancer death. Low-grade infiltrate was related to increasing T stage and an infiltrating margin.

Conclusion: Assessment of inflammatory infiltrate using Klintrup's criteria provides independent prognostic information on node-negative colorectal cancer. A high-grade local inflammatory response may represent effective host immune responses impeding tumour growth.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

Colorectal cancer is the second most common cause of cancer death in Western Europe and North America. Each year in the United Kingdom, there are approximately 35,000 new cases and 16,000 deaths attributable to this disease.¹ Overall survival is poor; even in those who undergo resection with curative intent, only half survive for five years.² Prognosis and thereby optimal treatment can be partly predicted by clinico-pathological criteria. Tumour stage, in terms of the ex-

tent of local spread and lymph node status, has long been recognised to predict outcome. This is the basis of the Dukes' and TNM staging systems that have four main categories.^{3,4}

However, some stages, e.g. Stage II (T3/4 N0, Dukes' B), include patients with a wide range of clinical outcomes. Additional clinically applicable prognostic features have therefore, been sought. Pathologically determined criteria that provide independent prognostic information following resection of node-negative colorectal cancer have been identified by Shepherd's group.⁴ These are: peritoneal

* Corresponding author. Tel.: +44 0141 211 5435; fax: +44 0141 552 3229.

E-mail address: campbellroxburgh@doctors.net.uk (C.S.D. Roxburgh).
0959-8049/\$ - see front matter © 2009 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2009.04.011

involvement, venous spread (both submucosal and extramural), spread to involve a surgical margin and perforation through the tumour. The so-called Petersen prognostic index (PI) combines these four factors in a simple cumulative scoring system. Patients have a worse outcome when more of these features are present. Thus in lymph node-negative disease, a group which makes up 40–50% of surgical resections for colorectal cancer,^{6,7} 5-year survival of 75–90% is reported; however, where high-risk pathological features are present survival is similar to that in node-positive disease.^{8,9} The Petersen Index can select patients at high risk of tumour recurrence who may benefit from adjuvant treatment and is validated in Dukes' B and C (single positive node) colorectal cancer.^{5,10}

Since the first study by Jass and colleagues,¹¹ the presence of a pronounced tumour inflammatory infiltrate has also been recognised as an important determinant of good outcome following potentially curative resection for colorectal cancer.^{12–14} More recently, Galon and co-workers¹⁵ concluded that the type and density of the immune cells in and around the tumour were a primary determinant of tumour progression. However, assessment of the tumour inflammatory infiltrate is not routinely performed: for example, the presence of tumour-infiltrating lymphocytes is listed as non-core data within the RCPATH guidelines.⁴ This is largely because its assessment has been perceived to be more subject to inter-observer variation than the standard staging and Petersen parameters.^{16,17} Recently, however, Klintrup and colleagues described a simplified method for the structured scoring of the inflammatory reaction at the tumours invasive edge.¹⁸ This includes all white cell types and results in a binary score of low grade or high grade.

The aim of the present study was to examine the prognostic value of a simple assessment of the tumour inflammatory infiltrate in addition to the routinely reported tumour pathological criteria including the Petersen Index in patients undergoing curative resection for node-negative colorectal cancer. Furthermore the prognostic value of inflammatory infiltrate and tumour margin characteristics in node-negative disease will be examined.

2. Materials and methods

Consecutive patients with histologically proven colorectal cancer who, on the basis of laparotomy findings and pre-operative abdominal computed tomography, were considered to have undergone potentially curative resection for node-negative colorectal cancer (Stages I and II) between January 1997 and June 2004 in a single surgical unit at Glasgow Royal Infirmary, were included in the study. Patients were identified from a prospectively maintained database. Clinical conditions known to acutely or chronically evoke a systemic inflammatory response were excluded from the present study. These include (i) emergency presentation (ii) clinical evidence of infection such as pyrexia and elevated white cell count and (iii) the presence of a chronic inflammatory condition. Patients receiving pre-operative radiotherapy were excluded from the study since radiotherapy has been reported to evoke an inflammatory response.^{19,20} Patients who died within 30

days of surgery were excluded from the analysis. The tumours were staged using the conventional Tumour, Node and Metastases classification (from the 5th edition and according to the Royal College of Pathologists Dataset 2007).⁴ All other pathological data were taken from the pathology reports issued at the time of resection.

The routine haematoxylin and eosin slides were retrieved from the pathology archives. A minimum of three slides per specimen were selected from the deepest area of tumour invasion and were scored according to both Jass'¹¹ and Klintrup's¹⁸ criteria. Klintrup's method is based on the deepest point of invasion identified from the three slides and this provides the overall score for the specimen.

Jass' scoring of slides was carried out as described previously.^{11,17} Briefly, the term 'peritumoural lymphocytic infiltrate' was applied to the stromal response at the tumours invasive edge. A specific and important feature of this response is the presence of a loose connective tissue lamina or cap (resembling lamina propria) at the deepest point of tumour penetration. The tumour glands are often heavily infiltrated by neutrophils but lymphocytes are not necessarily present in large numbers: it is the connective tissue stroma which is the most important feature. The tumours were scored on a two-point scale as peritumoural infiltrate either present or absent.

Klintrup's scoring of slides was carried out as described previously.¹⁸ Briefly, tumours were scored according to a four-point score. Scores were based on the appearances of tumour invasion at the deepest area. A score of 0 indicated that there was no increase in the inflammatory cells at the deepest point of the tumours invasive margin; score 1 denoted a mild and patchy increase in the inflammatory cells; score 2 denoted a prominent inflammatory reaction forming a band at the invasive margin with some evidence of destruction of cancer cell islands and score 3 denoted a florid cup-like inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell islands. These scores were then subsequently classified as low grade (scores 0 and 1) or high grade (scores 2 and 3) (Figs. 1 and 2).




Fig. 1 – Low-grade inflammatory cell infiltrate at the tumours invasive edge.




Fig. 2 – High-grade inflammatory cell infiltrate at the tumours invasive edge.

Assessment of tumour margin characteristics was also undertaken in accordance with Jass' criteria.^{11,17} Briefly, specific features of a diffusely infiltrating tumour margin include 'streaming dissection' of tumour cells through the muscularis propria, or the dissection of mesenteric adipose tissue by small glands or irregular clusters of cords of cells on microscopic examination.

A total of 100 tumour specimens were scored independently by two observers (CSDR and JMS), who were blinded to patient outcome, to confirm the consistency of scoring. Training was provided by a consultant pathologist (KO). The inter-observer intraclass correlation coefficients (ICCCs) provide a measure of the inter-observer agreement. The ICCCs for assessment of peritumoural inflammatory cell infiltrate were: 0.71 for Jass scoring and 0.81 for Klintrup's scoring. For assessment of tumour margin characteristics (expanding or infiltrating), the ICCC was 0.83 (ICCC values ≥ 0.6 are considered acceptable and ICCC value >0.7 is considered good). CSDR then scored all slides ($n = 200$) and these data were used in the analysis.

The Petersen Index was generated from the scores allocated to the four selected pathological variables present in a tumour specimen. Intra- or extramural vascular invasion, peritoneal involvement and surgical margin involvement were allocated a score of 1. Tumour perforation was allocated a score of 2. The total score is calculated and the PI is considered low risk where the score is 0 or 1 and high risk where the score is from 2 to 5.^{5,10}

In the Royal Infirmary, patients undergo regular follow-up (3 months, 6 months and then yearly to five years) with yearly CT scanning and regular colonoscopic surveillance until 5 years post-surgery. Information on date and cause of death was checked with that received by the cancer registration system and the Registrar General (Scotland). The study was approved by the Research Ethics Committee, Royal Infirmary, Glasgow.

2.1. Statistics

Grouping of the variables was carried out using standard thresholds. Univariate survival analysis and multivariate sur-

vival analysis with the calculation of hazard ratios (HRs) were performed using Cox's proportional-hazards model. A step-wise backward procedure was used to derive a final model of the variables that had a significant independent relationship with survival. To remove a variable from the model, the corresponding P value had to be greater than 0.1. Deaths up to August 2008 were included in the analysis. Inter-relationships between variables were assessed using contingency table analysis with the chi-squared test for trend as appropriate. Because of the number of statistical correlations, a P value <0.01 was considered to be significant. Analysis was performed using SPSS software (SPSS Inc., Chicago, IL, United States of America).

3. Results

Baseline clinico-pathological characteristics and relationship with cancer-specific survival of the patients with node-negative disease ($n = 200$) who underwent curative surgery for colorectal cancer are shown in Table 1. The majority of patients were 65 or older (68%), were male (55%) and had colon cancer (66%). Eighteen (9%) patients received adjuvant chemotherapy. Median number of lymph nodes sampled was 14 (range 1–41) for colonic tumours and was 12 (range 1–41) for rectal tumours. Sixty-two percent of the patients had 12 or more lymph nodes harvested (Table 1). Overall the mean number of lymph nodes sampled was 14, the frequency of extramural venous invasion was 24% and serosal involvement was 22%, in line with the current audit standards set by the Royal College of Pathologists.⁴

On routine pathological analysis, the minority of patients had an evidence of the 'high-risk' pathological features including poor tumour differentiation (9%), extramural vascular invasion (24%), peritoneal involvement (22%), margin involvement (8%), tumour perforation (3%) and perineural invasion (8%). The minority of patients were thus classed as low risk by the Petersen Index (11%). On assessment by Jass' criteria, 61% ($n = 121$) had tumour margins classed as expanding and the majority (74%, $n = 148$) had no peritumoural inflammatory infiltrate. On assessment using Klintrup's criteria, 59% ($n = 118$) patients were given a score of 0 or 1 (low-grade inflammation) and 41% ($n = 82$) were given a score of 2 or 3 (high-grade inflammation).

The minimum follow-up was 43 months; the median follow-up of the survivors was 73 months. No patients were lost to follow-up. During this period 76 patients died, 36 of their cancer. On univariate survival analysis of individual variables, age ($P < 0.01$), fewer than 12 nodes sampled ($P < 0.1$), vascular invasion ($P < 0.01$), peritoneal involvement ($P < 0.1$), tumour perforation ($P = 0.05$), the presence of an infiltrating invasive tumour margin ($P < 0.05$) and absent or a low-grade peritumoural inflammatory infiltrate score assessed by Klintrup's criteria ($P < 0.05$) were associated significantly with cancer-specific survival (Table 1).

On multivariate survival analysis of the significant variables for cancer-specific survival, age (HR 2.26, 95% CI 1.42–3.61, $P = 0.001$), high-risk Petersen Index (HR 2.45, 95% CI 1.08–5.45, $P = 0.032$), perineural invasion (HR 3.62, 95% CI 1.48–8.89, $P = 0.005$) and a low-grade peritumoural inflamma-

Table 1 – The relationship between clinico-pathological variables and cancer-specific survival in patients undergoing curative surgery for node-negative colorectal cancer.

	Patients n = 200 (%)	Univariate analysis hazard ratio (95% CI)	P value	Multivariate analysis hazard ratio (95% CI)	P value
Age					
<65 years	64 (32)				
65–74 years	70 (35)				
>75 years	66 (33)	1.92 (1.24–2.98)	0.004	2.26 (1.42–3.61)	0.001
Sex					
Female	90 (45)				
Male	110 (55)	0.86 (0.45–1.66)	0.659		
Site					
Colon	132 (66)				
Rectum	68 (34)	0.75 (0.36–1.55)	0.437		
Number of nodes harvested					
>12	123 (62)				
<12	77 (38)	1.88 (0.97–3.62)	0.060		0.134
T stage					
T1	7 (4)				
T2	22 (11)				
T3	126 (63)				
T4	45 (22)	1.48 (0.87–2.52)	0.152		
Adjuvant therapy					
No	182 (91)				
yes	18 (9)	1.42 (0.50–4.03)	0.507		
Differentiation					
Mod-well	183 (91)				
Poor	17 (9)	2.17 (0.84–5.61)	0.110		
Vascular invasion					
No	152 (76)				
Yes	48 (24)	2.63 (1.34–5.17)	0.005		
Peritoneal involvement					
No	157 (78)				
Yes	43 (22)	1.81 (0.90–3.61)	0.095		
Margin involvement					
No	186 (92)				
Yes	14 (8)	0.84 (0.20–3.50)	0.811		
Tumour perforation					
No	195 (97)				
Yes	5 (3)	4.23 (1.00–17.89)	0.050		
Petersen Index					
Low risk	179 (89)				
High risk	21 (11)	3.36 (1.52–7.46)	0.003	2.45 (1.08–5.45)	0.032
Perineural invasion					
No	185 (92)				
Yes	15 (8)	3.63 (1.59–8.29)	0.002	3.62 (1.48–8.89)	0.005
Invasive margin					
Expanding	121 (61)				
Infiltrating	79 (39)	1.95 (1.01–3.76)	0.046		0.407
Peritumoural infiltrate (Jass' criteria)					
Cap-like yes	52 (26)				
Cap-like no	148 (74)	2.00 (0.83–4.80)	0.122		
Peritumoural infiltrate (Klintrup's criteria)					
High-grade inflammation	82 (41)				
Low-grade inflammation	118 (59)	2.65 (1.21–5.82)	0.015	2.61(1.19–5.77)	0.017

Table 2 – The relationship between clinico-pathological variables and cancer-specific survival in patients with a low-risk Petersen Index following curative surgery for node-negative colorectal cancer.

	Patients n = 179 (%)	Univariate analysis hazard ratio (95% CI)	P value	Multivariate analysis hazard ratio (95% CI)	P value
Age					
<65 years	57 (32)				
65–74 years	63 (35)				
>75 years	59 (33)	2.01 (1.21–3.33)	0.005	2.31 (1.37–3.89)	0.002
Sex					
Female	77 (43)				
Male	102 (57)	0.96 (0.45–2.02)	0.907		
Number of nodes harvested					
>12	109 (61)				
<12	70 (39)	1.80 (0.86–3.79)	0.121		
T stage					
T1	7 (4)				
T2	22 (12)				
T3	125 (70)				
T4	25 (14)	1.04 (0.57–1.88)	0.908		
Adjuvant therapy					
No	166 (93)				
Yes	13 (7)	0.46 (0.06–3.40)	0.487		
Differentiation					
Mod-well	165 (92)				
Poor	14 (8)	2.51 (0.86–7.32)	0.091		0.198
Vascular invasion					
No	146 (82)				
Yes	33 (18)	1.46 (0.59–3.62)	0.409		
Peritoneal involvement					
No	154 (74)				
Yes	25 (26)	1.15 (0.44–3.03)	0.776		
Margin involvement					
No	176 (93)				
Yes	3 (7)	1.87 (0.25–13.94)	0.540		
Tumour perforation					
No	179 (97)				
Yes	0 (3)				
Perineural invasion					
No	169 (94)				
Yes	10 (6)	3.39 (1.18–9.79)	0.024	3.55 (1.20–10.55)	0.022
Invasive margin					
Expanding	111 (62)				
Infiltrating	68 (38)	2.07 (0.98–4.36)	0.055		0.246
Peritumoural infiltrate (Jass' criteria)					
Cap-like yes	48 (27)				
Cap-like no	131 (73)	2.40 (0.83–6.93)	0.105		
Peritumoural infiltrate (Klintrup's criteria)					
High-grade inflammation	76 (43)				
Low-grade inflammation	103 (57)	2.83 (1.15–6.98)	0.024	3.04 (1.22–7.58)	0.017

tory infiltrate assessed by Klintrup's criteria (HR 2.61, 95% CI 1.19–5.77, $P = 0.017$) were all independently associated with cancer-specific survival (Table 1).

One hundred and seventy nine patients with node-negative colorectal cancer were classed as low risk by the Petersen Index. In this group, on univariate survival analysis of individ-

ual variables, age ($P < 0.001$), poor tumour differentiation, ($P < 0.1$), perineural invasion ($P < 0.05$), the presence of an infiltrating invasive margin ($P < 0.1$) and absent or a low-grade peritumoural inflammatory infiltrate score assessed by Klinttrup's criteria ($P < 0.05$) were associated with cancer-specific survival (Table 2).

Table 3 – Inter-relationships between pathological variables in patients with a low-risk Petersen Index following potentially curative resection for node-negative colon cancer (n = 179).

	Node sample (<12/>12)	Diff (mod-well/poor)	VI (no/yes)	Peritoneal involvement (no/yes)	Margin involved (no/yes)	Perineural involvement (no/yes)	Tumour margin (expanding/infiltrating)	Jass' criteria (Yes/No)	Klintrup's criteria (Yes/No)
T stage (1/2/3/4)	0.943	0.218	0.993	<0.001	0.868	0.846	0.002	0.001	0.004
Node sample (>12/<12)		0.386	0.124	0.006	0.837	0.545	0.044	0.339	0.017
Differentiation (poor/mod-well)			0.310	0.403	0.612	0.141	0.697	0.637	0.975
Vascular invasion (yes/no)				0.011	0.408	<0.001	0.170	0.095	0.434
Peritoneal involvement (yes/no)					0.483	0.572	0.004	0.022	0.015
Margin involved (yes/no)						0.672	0.867	0.292	0.135
Perineural involvement (yes/no)							0.422	0.218	0.140
Tumour margin (expanding/infiltrating)								0.001	<0.001
Inflammatory cell infiltrate present (Jass' criteria) (yes/no)									<0.001

On multivariate survival analysis for cancer-specific survival in the low-risk Petersen Index group, age (HR 2.31, 95% CI 1.37–3.89, $P = 0.002$), perineural invasion (HR 3.55, 95% CI 1.20–10.55, $P = 0.022$) and a low-grade peritumoural inflammatory infiltrate assessed by Klintrup's criteria (HR 3.04, 95% CI 1.22–7.58, $P = 0.017$) were all independently associated with cancer-specific survival (Table 2).

When the patients who received adjuvant chemotherapy were removed from the analysis, age ($P < 0.1$), less than 12 nodes sampled ($P < 0.1$), poor tumour differentiation ($P < 0.05$), vascular invasion ($P < 0.05$), a high-risk Petersen Index ($P < 0.1$), perineural invasion ($P < 0.005$), an infiltrating tumour margin ($P < 0.1$), and a low-grade peritumoural inflammatory infiltrate assessed by Klintrup's criteria ($P < 0.05$) were associated with cancer-specific survival on univariate analysis. On multivariate analysis of these significant variables in patients who did not receive adjuvant chemotherapy, only age (HR 1.81, 95% CI 1.14–2.88, $P = 0.011$) and a low-grade peritumoural inflammatory infiltrate assessed by Klintrup's criteria (HR 2.46, 95% CI 1.10–5.48, $P = 0.028$) were independently associated with cancer-specific survival.

The inter-relationships between the individual pathological criteria in the low-risk Petersen Index group ($n = 179$) are shown in Table 3. Increasing T stage was directly related to the presence of peritoneal involvement ($P < 0.001$), an infiltrating tumour growth pattern and a low-grade peritumoural infiltrate assessed by both Jass' ($P < 0.01$) and Klintrup's criteria ($P < 0.01$). A lymph node sample less than 12 was directly related to the presence of peritoneal involvement ($P < 0.01$). The presence of vascular invasion was directly associated with the presence of perineural invasion ($P < 0.001$). Peritoneal involvement was directly associated with an infiltrating tumour growth pattern ($P < 0.01$). The presence of an infiltrating tumour growth pattern was associated with a low-grade inflammatory cell infiltrate assessed with Jass' ($P = 0.001$) and Klintrup's criteria ($P < 0.001$). Both Jass' and Klintrup's criteria were directly associated ($P < 0.001$).

4. Discussion

Following potentially curative resection for colorectal cancer there are a number of pathological features that guide treatment. Principal amongst these is the nodal disease which indicates a high likelihood of disease recurrence and the need for adjuvant therapy.^{3,21} In patients with no evidence of nodal disease, other pathological criteria have been proposed by Shepherd's group which identify patients at high risk of recurrence and which are now routinely reported.⁵ These include vascular invasion, peritoneal involvement, margin involvement and tumour perforation. These criteria have been combined in a score, the Petersen Index (PI), which reliably predicts poorer cancer-specific outcome in Dukes' B colon cancer.⁵ These findings have recently been validated in colorectal cancer by Quirke's group.¹⁰

In the present study of patients with node-negative colorectal cancer we have confirmed the finding that a high-risk PI is associated with poorer cancer-specific survival. However, the majority of patients (89%) were identified by the PI as low risk. Therefore, it was of interest that the presence of a low-

grade tumour inflammatory cell infiltrate (Klintrup's criteria) was associated with an approximately threefold poorer cancer-specific survival in these low-risk patients. In the present study, tumour inflammatory cell infiltrate assessed using Jass' criteria was also examined. However, in terms of predicting cancer-specific survival, Klintrup's criteria were superior to those of Jass. Taken together these results would suggest that tumour inflammatory cell infiltrate, in particular using Klintrup's criteria, should be considered for inclusion in the routine pathological reporting of colorectal cancer.

In the present study it was interesting that both Jass' and Klintrup's criteria were inversely associated with T stage and an infiltrating tumour margin. The presence of infiltrating growth pattern appears to be similar to the phenomenon known as de-differentiation, where there is a dissociation of tumour cells at the invasive front allowing these cells to migrate away from the main tumour, which may represent a morphological assessment of 'tumour aggressiveness'.²² This feature has also recently been described as 'tumour budding' where there is a transition from glandular structures to single cells or clusters of up to four cells in the invasive margin of colorectal tumours.²³ A high-grade local immune response may represent effective host cellular immune responses preventing the invasive margin from developing an infiltrating or budding appearance. These results are consistent with the detailed analysis of the tumour immune response in patients with colorectal cancer by Nielsen and co-workers¹³ and Galon and co-workers.¹⁵ Furthermore, the results of the present study are consistent with the concept that the type, density and location of a variety of immune cells, and not an individual immune cell type, are the important independent determinants of cancer-specific survival in patients with colorectal cancer.

Klintrup's method used in the present study differs from previous methods of assessing immune cells within the tumour as it is a structured assessment of all white cell types at the invasive margin. This technique can be applied to routine haematoxylin and eosin specimens with no special staining required. Previous assessments of peritumoural inflammation have been criticised for the subjective nature of the scoring methodology.^{16,17} In the present study the simple scoring method described by Klintrup was applied with relative ease and, as the low inter-observer variation demonstrates, it is reproducible. In the present study, Klintrup's scoring was undertaken using the original four-point method, which was subsequently modified to a two-point score (high grade and low grade) (Figs. 1 and 2). This methodology was similar to the original Klintrup's study and we would recommend a similar method be applied when classifying tumours in future studies.

With the introduction of whole population screening for colorectal cancer, earlier diagnosis should result in a higher proportion of early stage or node-negative disease being treated by clinicians. Therefore, the identification of high-risk pathological features in this cohort will be important in guiding provision of adjuvant therapy. The results of the present study have demonstrated that in addition to the existing routinely reported pathological features, other criteria such as low-grade peritumoural inflammation and the presence of an infiltrating tumour margin (which are currently listed in the Royal College

of Pathologists guidelines but as non-core data items) are significantly related to poor survival. These criteria may therefore, provide additional prognostic information, which could be used to inform multidisciplinary teams on treatment decisions. Currently, it is not known whether patients with pathological features such as low-grade inflammatory cell infiltrate would benefit from adjuvant systemic treatment; however, the same is true for other criteria such as vascular invasion and poor tumour differentiation.^{9,24} Which patients benefit from adjuvant therapy may become clearer as large adjuvant chemotherapy trials publish further results.

In summary, assessment of peritumoural inflammatory cell infiltrate provides independent prognostic information on node-negative disease and should therefore, be considered for future inclusion in routine pathological reporting of colorectal cancer.

Conflict of interest statement

None declared.

REFERENCES

1. Cancerstats. <www.cancerresearchuk.org>; 2004.
2. McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. *Br J Cancer* 2002;**86**:331–5.
3. Dukes CE, Bussey HJR. The spread of rectal cancer and its effect on prognosis. *Br J Cancer* 1958;**12**:309–20.
4. Williams TJ, Quirke P, Shepherd NA. RCPATH cancer services working group. Dataset for colorectal cancer. 2nd ed. <www.rcpath.org.uk>; 2007.
5. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. *Gut* 2002;**51**:65–9.
6. McArdle CS, McKee RF, Findlay IG, Wotherspoon H, Hole DJ. Improvement in survival following surgery for colorectal cancer. *Brit J Surg* 2005;**92**(8):1008–13.
7. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis* 2007;**22**(8):881–6.
8. Le Voyer T, Sigurdson E, Hanlon A, et al. Colon cancer survival is associated with increasing number of lymph nodes analysed: a secondary survey of intergroup trial INT-0089. *J Clin Oncol* 2003;**21**:2912–9.
9. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane database of systematic reviews 2008, Issue 3. Art. No.: CD005390. doi:10.1002/14651858.CD005390.pub2.
10. Morris EJ, Maughan NJ, Forman D, Quirke P. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. *Gut* 2007;**56**:1419–25.
11. Jass Jr, Love SB, Northover JM. A new prognostic classification of rectal cancer. *Lancet* 1987;**1**(8545):1303–6.
12. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. *J Pathol* 1997;**182**:318–24.
13. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. *J Pathol* 1999;**189**:487–95.
14. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systemic

- inflammatory response and survival in patients undergoing curative resection for colorectal cancer. *Br J Cancer* 2005;**92**(4):651–4.
15. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 2006;**313**(5795):1960–4.
16. Deans GT, Heatley M, Anderson N, et al. Jass' classification revisited. *J Am Coll Surg* 1994;**179**(1):11–7.
17. Jass JR, Ajikoka Y, Allen JP, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. *Histopathology* 1996;**28**:543–8.
18. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. *Eur J Cancer* 2005;**41**:2645–54.
19. Cengiz M, Akbulut S, Atahan IL, Grigsby PW. Acute phase response during radiotherapy. *Int J Radiat Oncol Biol Phys* 2001;**49**:1093–6.
20. Koc M, Taysi S, Sezen O, Bakan N. Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. *Biol Pharm Bull* 2003;**26**:1494–7.
21. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. *Ann Intern Med* 1995;**122**:321–6.
22. Gabbert H. Mechanism of tumor invasion: evidence from in vivo observations. *Cancer Metast Rev* 1985;**4**:293–309.
23. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. *Histopathology* 2002;**40**:127–32.
24. Benson AB, Shrag D, Somerfield MR, et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol* 2004;**22**(16):3408–19.